Syndicated Reports

Will The Majority Of Future Drugs Meet Orphan Drug Criteria?

Specialty Pharmacy Trends Report: Oncology

Healthcare Models, Measures and Methodology – 97 FAQs

What Are The Greatest challenges And Opportunities For Biosimilars In Emerging Markets?

Market Access Policy Relationships – Comparing Germany and France

ASCO 2014 — Delegate Physicians Rate Influence and Impact

Oncology Market Access Europe – Payer and Industry Perspectives

Medical Affairs Reputations In Oncology: Oncologists Rate Key Products and Companies

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities Into Sharp Focus

Biosimilar Index: Tracking the Biosimilar Development Landscape

Reshaping Medical Affairs: Delivering Value to KOLs and Payers

Market Access Team Management: Driving Exceptional Performance

Are You Managing Your Market Access Team For Success?

Stratifying High-Risk, High-Cost Patients

2013-14 Economics Report On Retail, Mail, And Specialty Pharmacies

Downloadable PDF By Adam J. Fein, Ph.D.

Progressions – Navigating the payer landscape

Biosimilars Report Collection

Healthcare Trends & Forecasts in 2014: Performance Expectations for the Healthcare Industry

What Does Healthcare Look Like In 2014?

HIN's Ninth Annual Industry Forecast-Get Your Copy Today!

HIN’s Ninth Annual Industry Forecast-What Does Healthcare Look Like In 2014?

Healthcare Trends & Forecasts in 2014: Performance Expectations for the Healthcare Industry, HIN's ninth annual industry forecast, provides both a handle on what's keeping healthcare CEOs up at night and a dream prescription for sounder program management in 2014. (Source: Healthcare Intelligence Network, December, 2013). Available for purchase now.

Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance

This Healthcare Intelligence Network (HIN) report, Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance, explores emerging models of episode-based payments, physician-hospital organizations and physician bonus structures.

Purchase your copy here.

Benchmarking the Pharma Industry’s HEOR Functions

This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies. Download Report Preview here. (Source: ISR reports, 2013).

Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

Healthcare Intelligence Network – Guide to Accountable Care Organizations

Technology’s Role in Enhancing and Expanding Medical Information Teams’ Capabilities

Health Outcomes Liaisons (HOLs) Serve as Key Bridge between Pharmaceutical Sector and Managed Care Groups

Health Outcomes Liaisons (HOLs) Serve as Key Bridge between Pharmaceutical Sector and Managed Care Groups

2012-13 Economic Report on Retail, Mail and Specialty Pharmacies

For anyone who wants to understand and benefit from the forces reshaping the highly competitive U.S. pharmacy industry, the 2012

Real World Data and its Healthcare Applications Report

The Real World Data Report is a crucial up-to-date, independent and strategic insight into the most cutting edge real world data practices. The report extract, with contributions from GSK, NovoNordisk, Pfizer, Sanofi, Janssen, BMS and Amgen as well the AHRQ shares data sources they use and how they deal with issues such as data gaps, non- standardization and retrospective study data.

Health Economics and Outcomes Research

Pricing pressure and regulatory restrictions across various healthcare industries have called for more detailed evidence of outcomes of healthcare products. In order to gain market access, medical technology manufacturers must be able to demonstrate the clinical and economic evidence to providers, healthcare decision-makers and payers to be able to remain competitive.

Categories

Stay Connected